HEALTH TECHNOLOGY

NVIDIA Launches UK’s Most Powerful Supercomputer, for Research in AI and Healthcare

NVIDIA | July 07, 2021

NVIDIA today officially launched Cambridge-1, the United Kingdom’s most powerful supercomputer, which will enable top scientists and healthcare experts to use the powerful combination of AI and simulation to accelerate the digital biology revolution and bolster the country’s world-leading life sciences industry.


Dedicated to advancing healthcare, Cambridge-1 represents a $100 million investment by NVIDIA. Its first projects with AstraZeneca, GSK, Guy’s and St Thomas’ NHS Foundation Trust, King’s College London and Oxford Nanopore Technologies include developing a deeper understanding of brain diseases like dementia, using AI to design new drugs and improving the accuracy of finding disease-causing variations in human genomes.


Cambridge-1 brings together decades of NVIDIA’s work in accelerated computing, AI and life sciences, where NVIDIA Clara™ and AI frameworks are optimized to take advantage of the entire system for large-scale research. An NVIDIA DGX SuperPOD™ supercomputing cluster, it ranks among the world’s top 50 fastest computers and is powered by 100 percent renewable energy.


“Cambridge-1 will empower world-leading researchers in business and academia with the ability to perform their life’s work on the U.K.’s most powerful supercomputer, unlocking clues to disease and treatments at a scale and speed previously impossible in the U.K.,” said Jensen Huang, founder and CEO of NVIDIA. “The discoveries developed on Cambridge-1 will take shape in the U.K., but the impact will be global, driving groundbreaking research that has the potential to benefit millions around the world.”
Cambridge-1 builds on the U.K.’s status as a global leader in life sciences, technology and AI by providing advanced infrastructure for current and future generations to carry out groundbreaking research within the country.


According to a report by Frontier Economics, an economics consulting firm, Cambridge-1 has the potential to create an estimated value of £600 million (about $825 million) over the next 10 years.


AstraZeneca: Transforming Drug Discovery with AI


NVIDIA is collaborating with AstraZeneca to fuel faster drug discoveries by creating a transformer-based generative AI model for chemical structures. Transformer-based neural network architectures, which have become available only in the last several years, allow researchers to leverage massive datasets using self-supervised training methods, avoiding the need for manually labeled examples during pre-training.


The MegaMolBART drug discovery model is being used in reaction prediction, molecular optimization and de novo molecular generation and will optimize the drug development process. It is based on AstraZeneca’s MolBART transformer model and is being trained on the ZINC chemical compound database — using NVIDIA’s Megatron framework to enable massively scaled-out training on supercomputing infrastructure. This open-source model will be available to researchers and developers in the NVIDIA NGC™ software catalog.


NVIDIA and AstraZeneca have a separate project on Cambridge-1 focused on the use of AI in digital pathology. In digital pathology, significant time and money are spent annotating whole slide images of tissue samples, to aid the search for new insights. By using unsupervised AI algorithms trained on thousands of images, it is possible to remove the process of annotating while simultaneously finding potential imaging features that correlate with drug response.


“Training AI algorithms on whole slide images is challenging in part due to the size of the images,” said Lindsay Edwards, vice president of Data Science and AI, Respiratory and Immunology, BioPharmaceuticals R&D at AstraZeneca. “Working with NVIDIA on Cambridge-1 enables us to scale our current work and develop new methodologies advancing the use of AI in digital pathology.”


GSK: Steering Great Science with Partners for Patients


GSK’s research and development approach includes a focus on genetically validated targets, which are twice as likely to become medicines and now make up more than 70 percent of its research pipeline. To maximize the potential of these insights, GSK has built state-of-the-art capabilities at the intersection of human genetics, functional genomics, and artificial intelligence and machine learning.


“Advanced technologies are core to GSK’s R&D approach and help to unlock the potential of large, complex data through predictive modeling at new levels of speed, precision and scale,” said Dr. Kim Branson, senior vice president and global head of AI-ML at GSK. “We are pleased to have the opportunity to partner with NVIDIA to deliver on GSK’s drug discovery ambition and contribute to the U.K.’s rich life sciences ecosystem — both aims that have patient benefit at the centre.”


Working with partners at the cutting edge of genetics, genomics and AI/ML can ultimately help GSK predict more about human health, and develop better medicines that are twice as likely to succeed in the clinic and go on to become approved therapies that benefit patients. Access to Cambridge-1 will contribute additional computational power and state-of-the-art AI technology to GSK’s drug discovery process.


King’s College London & Guy’s and St Thomas’ NHS Foundation Trust: AI-Generated Synthetic Brain Data


King’s College London and Guy’s and St Thomas’ NHS Foundation Trust are using Cambridge-1 to teach AI models to generate synthetic brain images by learning from tens of thousands of MRI brain scans, from various ages and diseases. The ultimate goal is to use this synthetic data model to gain a better understanding of diseases like dementia, stroke, brain cancer and multiple sclerosis and enable earlier diagnosis and treatment.


As this AI synthetic brain model can generate an infinite amount of never-seen brain images with chosen characteristics (age, disease, etc.), it will allow a better and more nuanced understanding of what diseases look like, possibly enabling an earlier and more accurate diagnosis.


“Through this partnership, we will be able to use a scale of computational power that is unprecedented in healthcare research,” said Professor Sebastien Ourselin, head of the School of Biomedical Engineering & Imaging Sciences at King’s College London. “It will be truly transformational for the health and treatment of patients.”


This research leverages several of the U.K.’s world-leading healthcare resources through close collaboration with the National Health Service and the UK Biobank, one of the richest biomedical databases in the world. King’s College London intends to share this synthetic data model with the greater research and startup community.


“The power of artificial intelligence in healthcare will help to speed up diagnosis for patients, improve services such as breast cancer screening, and support the way that we risk assess and prioritize patients according to clinical need,” said Professor Ian Abbs, chief executive officer of Guy’s and St Thomas’ NHS Foundation Trust. “We are excited about our involvement in the Cambridge-1 data center as it will enable us to be amongst the first to benefit from these new AI capabilities — using the very latest technology to benefit our patients, as well as manage precious resources more efficiently.”


Oxford Nanopore: Scalable, Real-Time Genomics


Oxford Nanopore Technologies’ long-read sequencing technology is being used in more than 100 countries to gain genomic insights across a breadth of research areas — from human and plant health to environmental monitoring and antimicrobial resistance.


Oxford Nanopore deploys NVIDIA technology in a variety of genomic sequencing platforms to develop AI tools that improve the speed and accuracy of genomic analysis. With access to Cambridge-1, Oxford Nanopore will be able to carry out tasks relating to algorithm improvement in hours rather than days. These improved algorithms will ensure improved genomic accuracy for greater insights and quicker turnaround times in scientists’ hands.


“Harnessing the power of Cambridge-1 will help us further speed up our algorithm development to support powerful, accurate genomic analysis,” said Rosemary Sinclair Dokos, vice president of Product and Programme Management at Oxford Nanopore. “This will in turn enable the scientists using our technology on the ground to gain more insights than ever before, across a breadth of research areas.”


About Cambridge-1
Cambridge-1 is the first NVIDIA supercomputer designed and built for external research access. The company will collaborate with researchers to make much of this work available to the greater scientific community.


About NVIDIA
NVIDIA’s (NASDAQ: NVDA) invention of the GPU in 1999 sparked the growth of the PC gaming market and has redefined modern computer graphics, high performance computing and artificial intelligence. The company’s pioneering work in accelerated computing and AI is reshaping trillion-dollar industries, such as transportation, healthcare and manufacturing, and fueling the growth of many others. 

Spotlight

Would you believe there are actual medical conditions called Christmas Disease, Nutcracker Syndrome, and Grinch Syndrome? We promise, we’re not being naughty and making it up. Although they’re rare, these conditions are real, and they affect the blood, heart, and blood vessels, causing serious symptoms like pain, bleeding, and fainting. Hemophilia B, also known as Christmas Disease, is a rare genetic disorder that does not allow blood to properly clot due to insufficient levels of blood protein called Factor IX. This is the second most common type of hemophilia.


Other News
HEALTH TECHNOLOGY

BulletinHealthcare Launches Family Medicine Today in Partnership with American Academy of Family Physicians

BulletinHealthcare | August 16, 2022

BulletinHealthcare, a leading provider of news briefings for top U.S. medical associations, announced that it has launched its latest briefing for members of the American Academy of Family Physicians Family Medicine Today. Family Medicine Today is distributed via email to AAFP members by 9:00 a.m. ET every weekday morning. The publication provides family medicine physicians with relevant medical, practice management, and health policy news, delivered directly to their inbox in a concise, user-friendly format. The content of the briefings follows BulletinHealthcare's signature curation and distillation of the day's most important news stories, selected from thousands of sources by its team of healthcare analysts. "We are pleased to partner with the American Academy of Family Physicians to produce an exciting publication to serve their members. Our analyst group is unmatched in their expertise in producing handcrafted news briefings for busy healthcare professionals. And, with this new partnership, BulletinHealthcare adds a valuable new audience to the nearly one million healthcare professionals we reach each day." Danielle Sturgis, Vice President of Partnerships at BulletinHealthcare "The typical family physician sees more than 80 patients a week. As advocates for family physicians and their patients, the AAFP works to deliver high-value resources that give our members more time and energy for their patients," said Shawn Martin, Executive Vice President and Chief Executive Officer of the American Academy of Family Physicians. "In Family Medicine Today, BulletinHealthcare will curate content specifically for family physicians, providing a quick and convenient way for our members to stay current on news and trends that affect family medicine." Advertising opportunities in AAFP's Family Medicine Today are now available, including special founding advertiser packages for 2022. About BulletinHealthcare BulletinHealthcare, a Cision® Insights solution, is a healthcare provider-focused digital publisher that – through partnerships with more than 30 leading medical associations and the Cleveland Clinic – curates and disseminates the stories and research that matter most to verified physicians, dentists, nurses, and other HCPs. BulletinHealthcare delivers nearly one million briefings every weekday to our partners' members and stakeholders. About the American Academy of Family Physicians Founded in 1947, the AAFP represents 127,600 physicians and medical students nationwide. It is the largest medical society devoted solely to primary care. Family physicians conduct approximately one in five office visits -- that's 192 million visits annually or 48 percent more than the next most visited medical specialty. Today, family physicians provide more care for America's underserved and rural populations than any other medical specialty. Family medicine's cornerstone is an ongoing, personal patient-physician relationship focused on integrated care.

Read More

HEALTH TECHNOLOGY

Addison Group Expands Non-Clinical Healthcare Services With Acquisition of Harmony Healthcare

Addison Group | July 11, 2022

Addison Group a national leader in professional services specializing in talent solutions and consulting services, announced the acquisition of Harmony Healthcare a human capital management company providing a diverse range of non-clinical healthcare workforce and consulting solutions nationwide. With healthcare as the third-largest industry in the U.S., this investment comes amid high demands and a continued shortage of non-clinical healthcare workers. Addison and Harmony's combined 28 years of experience in non-clinical healthcare workforce solutions enable health organizations to thrive in an ever-changing environment. The acquisition furthers Addison's position as a national leader in non-clinical healthcare talent resources, recruiting, and consulting services, and Addison's ongoing expansion strategy through organic growth and acquisitions of forward-thinking specialized firms that prioritize client and employee satisfaction. "Addison's consistent growth trajectory is due to our keen understanding of market trends and finding the right solutions for our client's business challenges. As the healthcare industry continues to navigate significant shifts, many organizations are still grappling with talent shortages, cyberattacks, and the rising cost of health services. Our ongoing investment in non-clinical healthcare workforce solutions provides our clients with innovative, accessible, and value-based health system resources. Together with Harmony, we will continue to empower our shared client base with enhanced consultant services within health information technology, reimbursement, and population health." Thomas Moran, CEO of Addison Group "Addison's consultative approach and expansive network of professionals will accelerate our abilities to meet customer demands nationally. Addison's culture focuses on People First, and the vast range of offerings provides our employees and consultants with added career opportunities. We are excited to partner with Addison as we continue our mission to empower healthcare organizations with quality solutions that optimize financial and clinical outcomes while enabling change management required to navigate the rapidly shifting healthcare landscape," said Brandon Martin, President of Harmony Healthcare. Harmony Healthcare will continue to maintain its headquarters in Tampa, Florida. The company's executives and the team will retain their roles with a continued focus on expanding their organization. About Addison Group Addison Group is a leading professional services firm specializing in talent solutions and consulting. Addison Group delivers companies' expertise and talent to achieve and sustain business growth. We offer a full suite of consulting and recruiting capabilities across multiple sectors, including information technology, finance and accounting, non-clinical healthcare, human resources, administrative, and digital marketing. With a growing network of companies, offices across the United States, and deep relationships in regional and local markets, Addison Group is one of the top talent solutions and consulting companies in the US, providing industry-leading expertise with a national reach and a localized touch. Founded in 1999, Addison Group has been repeatedly recognized by the media as one of the fastest-growing private companies in the United States, Forbes' Top 200 America's Best Professional and Specialist Search Firms, America's Best Recruiters and Executive Search Firms, and America's Best Temporary Staffing Firms, SIA Top 100 Staffing Bold Leaders, Inc. Best 100 Places to Work, and Best of Staffing® by ClearlyRated. About Harmony Healthcare Harmony Healthcare, a human capital management company, provides a diverse range of non-clinical staffing and consulting solutions to healthcare organizations nationwide. Harmony Healthcare delivers quality solutions to empower healthcare organization success, enhance clinical and financial outcomes, and enable the transition to value-based healthcare. Harmony Healthcare is a trusted partner to over 300 clients, including 11 of the top 15 largest health systems in the nation, major academic health centers, hospitals, physician practices, payers, 9 of the 15 largest CPA firms, and the federal government. Founded in 2010, Harmony Healthcare is a proud member of several prestigious professional health organizations including ACDIS, HFMA, AHIMA, NCAR, NAHRI, AAHAM, NAHAM, ACHE, AHDI, ACMA, NAHQ, CMSA, and ASHRM.

Read More

HEALTH TECHNOLOGY

Paradigm Oral Health Announces Acquisition by BlackRock Long Term Private Capital

Paradigm Oral Health | September 23, 2022

Paradigm Oral Health a leading oral surgery and digital dentistry platform announced that BlackRock Long Term Private Capital has entered into a definitive agreement to acquire a majority interest in the company from shareholders including InTandem Capital Partners. LTPC will partner with Paradigm’s executive leadership team, led by founder and CEO Dr. David Rallis, to support the company’s continued expansion and strategic growth plans. Founded in 2018, Paradigm has developed an industry-leading model designed to attract and retain best-in-class surgeons focused on delivering the highest quality of oral health care and dental implant surgery while fostering a medically-driven, patient-friendly culture of excellence. The company partners with leading oral surgery groups in markets across the United States, allowing them to maintain their unique brand identity while operating on the same platform. Paradigm’s proprietary practice management technology, Paragon, utilizes cutting-edge technology and data analytics to provide and store proprietary information and intelligence generated by the business, leading to enhanced performance as well as increased patient and provider satisfaction. Today, Paradigm and its team of over 100 surgeon partners provide patient care in 75 state-of-the-art facilities throughout the United States. “We are pleased to invest in Paradigm, which has established itself as an industry defining platform for the development and delivery of next-generation oral health solutions. Through its focus on providing superior clinical care, advanced technology, and continued training and education to its surgeon partners, the company is well positioned for long-term growth. We look forward to partnering with Dr. David Rallis and the entire Paradigm team.” Colm Lanigan, Head of BlackRock LTPC, Americas David Rallis, DDS, MD, and CEO of Paradigm Oral Health, commented, “Paradigm is advancing oral surgical outcomes and patient experience through a culture that places the needs of the patient first. At Paradigm, we validate our clinical performance through a proprietary data ecosystem and use data to reinforce our culture of excellence and accountability. Through innovation, and the rapid adoption of technology, we continue to set the standard for dental implant surgery. Aligning our company with world-class partners, first InTandem Capital and now BlackRock LTPC, has allowed Paradigm to emerge as a leader. We are humbled by the opportunity to partner with BlackRock LTPC, and excited to work with Colm Lanigan and his team as we continue to advance Paradigm as the global leader in oral surgery.” Elliot Cooperstone, Managing Partner of InTandem Capital Partners, Paradigm’s financial sponsor since 2019, commented, “InTandem Capital invests in healthcare companies that are local leaders with the ambition and potential to become a national powerhouse. Dr. David Rallis and the leadership team at Paradigm embraced our playbook for accelerated growth with amazing skill and dedication. Our deep trust in each other has allowed our partnership to flourish. My colleagues and I wish David and the Paradigm team the very best as they build on their well-deserved position as the country’s leading oral health company.” Paradigm is BlackRock LTPC’s sixth investment to date and its fourth investment in North America. Houlihan Lokey acted as financial advisor and Goodwin Procter acted as legal advisor to Paradigm. Simpson Thacher acted as legal advisor to Blackrock LTPC. About Paradigm Oral Health Paradigm Oral Health is the preeminent provider of oral surgery. Paradigm’s uniqueness comes from their ability to hire the most elite oral surgeons in the country and train them on their proprietary platform of excellence. Paradigm Oral Health continues to revolutionize and reinvent implant surgery through their ongoing technology and digital work-flow advancements. With a passion for excellence, Paradigm embraces every opportunity to meet the needs of their patients and referring dentists. About BlackRock LTPC BlackRock LTPC is an innovative private equity strategy focused on investing in high-quality businesses and value creation through active collaboration with management teams. The strategy's flexible duration and prudent approach to leverage preserve optionality for growth and help enable compounded capital appreciation. LTPC's team of 23 professionals are based in New York and London and invest across North America and Western Europe. LTPC is backed by BlackRock, Inc., which manages $320 billion in alternative investments and commitments on behalf of clients worldwide as of June 30, 2022. About InTandem Capital Partners InTandem Capital Partners is a private equity firm that invests in and helps accelerate the growth of select healthcare services companies. Its goal is to build excellent businesses of significant value working collaboratively with its management team partners. InTandem is comprised of former business executives and experienced investors, and is uniquely qualified to provide strategic, acquisition and operating expertise to help companies significantly increase their value over time. InTandem provides active support to the management of its portfolio companies directly and leverages its network of industry executives to augment its capabilities.

Read More

HEALTH TECHNOLOGY

Signify Health Receives NCQA’s HEDIS Allowable Adjustments Certification

Signify Health | September 26, 2022

Signify Health a leading healthcare platform that leverages advanced analytics, technology, and nationwide healthcare networks to create and power value-based payment programs, has again achieved the National Committee for Quality Assurance certification for the Healthcare Effectiveness Data and Information Set. This is the second year in which the Company has received this certification. NCQA provides accreditations and certifications to evaluate a wide range of organizations across the healthcare system. More than 90 percent of health plans in the United States, covering 190 million people, rely on NCQA’s HEDIS measurement tool. The methodology that Signify Health uses to identify Medicare members who have gaps in their care and would benefit from in-home diagnostic testing was evaluated and certified by NCQA. Receiving this certification allows Signify Health to provide services that align with the industry's most rigorous data assessment processes, resulting in more accurate and timely clinical services for eligible members. “Through our comprehensive data set and analytics, Signify Health is able to effectively identify at-risk patients and connect them with the appropriate diagnostic and preventive services. We are proud to once again have achieved this NCQA certification, demonstrating our ability to effectively identify gaps in care and to support access to high-quality health services.” Marc Rothman, MD, Chief Medical Officer, Signify Health NCQA HEDIS measures relate to many of the most significant chronic health conditions facing seniors in Medicare. In 2021, Signify Health announced the certifications for diabetes care, kidney health evaluation in patients with diabetes, colorectal cancer screening, and osteoporosis management in women. In 2022, Signify Health was recertified for all of the measures from 2021 that are still recognized by NCQA and expanded its certification to include osteoporosis screening as a preventive measure for older women who have not had a fracture. Osteoporosis is a serious bone disease that impacts the quality of life, especially for women aged 67-85. With the appropriate screenings and interventions, the risk of future bone fractures related to osteoporosis can be reduced. HEDIS® is a registered trademark of the National Committee for Quality Assurance. NCQA Measure Certification Program™ is a trademark of the National Committee for Quality Assurance. About Signify Health Signify Health is a leading healthcare platform that leverages advanced analytics, technology, and nationwide healthcare provider networks to create and power value-based payment programs. Our mission is to build trusted relationships to make people healthier. Our solutions support value-based payment programs by aligning financial incentives around outcomes, providing tools to health plans and healthcare organizations designed to assess and manage risk and identify actionable opportunities for improved patient outcomes, coordination and cost-savings. Through our platform, we coordinate what we believe is a holistic suite of clinical, social, and behavioral services to address an individual’s healthcare needs and prevent adverse events that drive excess cost, all while shifting services towards the home. About NCQA NCQA is a private, nonprofit organization dedicated to improving health care quality. NCQA accredits and certifies a wide range of health care organizations. It also recognizes clinicians and practices in key areas of performance. NCQA’s Healthcare Effectiveness Data and Information Set is the most widely used performance measurement tool in health care.

Read More

Spotlight

Would you believe there are actual medical conditions called Christmas Disease, Nutcracker Syndrome, and Grinch Syndrome? We promise, we’re not being naughty and making it up. Although they’re rare, these conditions are real, and they affect the blood, heart, and blood vessels, causing serious symptoms like pain, bleeding, and fainting. Hemophilia B, also known as Christmas Disease, is a rare genetic disorder that does not allow blood to properly clot due to insufficient levels of blood protein called Factor IX. This is the second most common type of hemophilia.

Resources